Sandoz licenses three Henlius biosimilars for global commercialization
Sandoz has struck a collaboration with Shanghai Henlius to secure commercialization rights outside China for three early-stage biosimilars: evolocumab (Repatha), belimumab (Benlysta) and cetuximab (Erbitux). The agreement includes up to $100.5 million up front for initial assets and up to $322 million total with milestones, while Henlius will continue development and manufacture and retain China rights. The deal raises Sandoz's biosimilars pipeline to 39 assets with potential to reach 46, follows a prior Henlius Yervoy deal, and aligns with Sandoz's plan for a standalone biosimilars unit amid looming patent expiries.
Sandoz gains global rights to three Henlius biosimilars.
Context
Many biologic drugs will lose patent protection in coming years. Sandoz and Henlius have already made a similar Yervoy deal in April 2025. The companies could add more assets and pursue regulatory approvals next.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked